Childhood Cancer Survivor Study Cohort

The CCSS cohort consists of previously untreated patients diagnosed prior to 21 years of age with leukemia, lymphoma, central nervous system cancer, neuroblastoma, bone or soft tissue sarcoma, or kidney cancer, who survived for at least five years after the date of diagnosis. Survivors were diagnosed between January 1, 1970 and December 31, 1986 at one of 26 participating institutions. The study design, cohort characteristics and outcomes ascertained are presented in detail elsewhere [12 (link)–14 (link)]. The CCSS was approved by the Institutional Review Board at each participating institution, and informed consent for participation was obtained from all subjects who were 18 or more years of age, or their parents, if the subject was less than 18 years of age.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Green D.M., Nolan V.G., Goodman P.J., Whitton J.A., Srivastava D., Leisenring W.M., Neglia J.P., Sklar C.A., Kaste S.C., Hudson M.M., Diller L.R., Stovall M., Donaldson S.S, & Robison L.L. (2013). The Cyclophosphamide Equivalent Dose as an Approach for Quantifying Alkylating Agent Exposure. A Report from the Childhood Cancer Survivor Study. Pediatric blood & cancer, 61(1), 53-67.

Publication 2013

Bone Institutional review board Kidney cancer Leukemia Lymphoma Nervous system cancer Neuroblastoma Parents Patients Soft tissue sarcoma Survivors

Corresponding Organization :

Other organizations : St. Jude Children's Research Hospital, University of Memphis, Fred Hutch Cancer Center, University of Minnesota Medical Center, Memorial Sloan Kettering Cancer Center, University of Tennessee Health Science Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Stanford University, Stanford Medicine

Top 5 similar protocols

Protocol cited in 69 other protocols

Variable analysis

independent variables

None explicitly mentioned

dependent variables

Survival for at least five years after the date of diagnosis

control variables

Previously untreated patients diagnosed prior to 21 years of age with leukemia, lymphoma, central nervous system cancer, neuroblastoma, bone or soft tissue sarcoma, or kidney cancer
Survivors diagnosed between January 1, 1970 and December 31, 1986 at one of 26 participating institutions

positive controls

None specified

negative controls

None specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!